

DAFTAR PUSTAKA

1. Kaneda Y, Horiki N, Cheng XJ, Fujita Y, Maruyama M, Tachibana H. Ribodemes of *Blastocystis hominis* isolated in Japan. *Am J Trop Med Hyg.* 2001;65(4):393-396.
2. Baker CJ, editor. Red book atlas of pediatric infection diseases. 3rd ed. *American Academy of Pediatrics.* 2017;16:62.
3. Stenzel DJ, Boreham PFL. *Blastocystis hominis* revisited. *Clin Microbiol Rev.* 1996;9(4):563-584.
4. Stark D, Barratt JLN, Van Hal S, Marriott D, Harkness J, Ellis JT. Clinical significance of enteric protozoa in the immunosuppressed human population. *Clin Microbiol Rev.* 2009;22(4):634-650.
5. Kok M, Cekin Y, Cekin AH, Uyar S, Harmandar F, Sahinturk Y. The role of *Blastocystis hominis* in the activation of ulcerative colitis. *Turk J Gastroenterol.* 2019;30(1):40-6.
6. Kain KC, Noble MA, Freeman HJ, Barteluk RL. Epidemiology and clinical features associated with *Blastocystis hominis* infection. *Diagn Microbiol Infect Dis.* 1987;8(4):235-244.
7. Al-Fellani MA, Khan AH, Al-Gazoui RM, Zaid MK, Al-Ferjani MA. Prevalence and clinical features of *Blastocystis hominis* infection among patients in Sebha, Libya. *Sultan Qaboos Univ Med J.* 2007;7(1):6.
8. Nimri LF. Evidence of an epidemic of *Blastocystis hominis* infections in preschool children in northern Jordan. *J Clin Microbiol.* 1993;31(10):2706-2708.
9. Yakoob J, Jafri W, Jafri N, Khan R, Islam M, Beg AM, Zaman V. *Irritable bowel syndrome: In search of an etiology: role of Blastocystis hominis.* *Am J Trop Med Hyg.* 2004;70(4):383-385.
10. Nascimento SA, Moitinho MDLR. *Blastocystis hominis* and other intestinal parasites in a community of Pitanga city, Paraná State, Brazil. *Rev Inst Med Trop Sao Paulo.* 2005;47(4):213-217.

11. Minvielle MC, Pezzani BC, Cordoba MA, De Luca MM, Apezteguia MC, Basualdo JA. Epidemiological survey of *Giardia* spp. and *Blastocystis hominis* in an Argentinian rural community. *Korean J Parasitol.* 2004;42(3):121-127.
12. Leelayoova S, Rangsin R, Taamasri P, Naaglor T, Thathaisong U, Mungthin M. Evidence of waterborne transmission of *Blastocystis hominis*. *Am J Trop Med Hyg.* 2004;70(6):658-662.
13. Baldo ET, Belizario VY, De Leon WU, Kong HH, Chung D II. Infection status of intestinal parasites in children living in residential institutions in Metro Manila, the Philippines. *Korean Journal of Parasitology.* 2004;42(2):67-70.
14. Greige S, El Safadi D, Bécu N, Gantois N, Pereira B, Chabe M, Vanneste SB, Certad G, Hage RE, Chemaly M, Hamze M, Viscogliosi E. Prevalence and subtype distribution of *Blastocystis* sp. isolates from poultry in Lebanon and evidence of zoonotic potential. *Parasites and Vectors.* 2018;11(1):1-10.
15. Mardani Kataki M, Tavalla M, Beiromvand M. Higher prevalence of *Blastocystis hominis* in healthy individuals than patients with gastrointestinal symptoms from Ahvaz, southwestern Iran. *Comp Immunol Microbiol Infect Dis.* 2019;65:160-164.
16. Deng Y, Zhang S, Ning C, Zhou Y, Teng X, Wu X, Chu Y, Yu Y, Chen J, Tian L, Wang W. Molecular epidemiology and risk factors of *Blastocystis* sp. infections among general populations in Yunnan Province, southwestern China. *Risk Manag Healthc Policy.* 2020;13:1791-1801.
17. Sari IP, Benung MR, Wahdini S, Kurniawan A. Diagnosis and identification of *Blastocystis* subtypes in primary school children in Jakarta. *J Trop Pediatr.* 2018;64(3):208-214.
18. Wahdini S, Sudarmono P, Wardhana AW, Irmawati FP, Haswinzky RA, Dwinastiti YA, Sungkar S. Penyakit parasitik pada anak sekolah berasrama di Kabupaten Bogor. *J Kedokt Indones.* 2018;6(3):1-5.
19. Nofita E, Harminarti N, Rusjdi SR. Identifikasi *Blastocystis hominis* secara mikroskopis dan PCR pada sampel feses di Laboratorium RSUP. Dr. M. Djamil Padang. *Maj Kedokt Andalas.* 2014;37(1):6.

20. Salim HR, Kumar GS, Vellayan S, Mak JW, Anuar AK, Init I, Vennila GD, Saminathan R, Ramakrishan K. *Blastocystis* in animal handlers. *Parasitol Res.* 1999;85(12):1032-1033.
21. Brown KH. Symposium: nutrition and infection, prologue and progress since 1968 The history of nutrition: malnutrition, infection and immunity. *Journal of Nutrition.* 2003;133:336-340.
22. Kaczmarek A, Gołab E, Żarnowska-Prymek H, Rawska A, Janczak D, Lewicki A, *et al.* Genetic diversity of *Blastocystis hominis* sensu lato isolated from humans in Poland. *Przegl Epidemiol.* 2017;71(4):539-546.
23. Stensvold CR, Smith HV, Nagel R, Olsen KE, Traub RJ. Eradication of *Blastocystis* carriage with antimicrobials: reality or delusion?. *J Clin Gastroenterol.* 2010;44(2):85-90.
24. Coyle CM, Varughese J, Weiss LM, Tanowitz HB. *Blastocystis*: to treat or not to treat...*Clin Infect Dis.* 2012;54(1):105-110.
25. Sohaila MR, Fischer PR. *Blastocystis hominis* and travelers. *Travel Medicine and Infectious Disease.* 2005;3,33–38.
26. Tan, K. S.W. New insights on classification, identification, and clinical relevance of *Blastocystis spp.* *Clinical Microbiology Reviews.* 2008;21(4):639-665.
27. Ceruelos AH, Romero-quezadaRuvalcaba JC, Contreras LL. Therapeutic uses of metronidazole and its side effects: an update. *European Review for Medical and Pharmacological Sciences.* 2019;23:397-401.
28. Belleza MLB, Cadacio JLC, Borja MP, Solon JAA, Padilla MA, Tongol-Rivera PN, *et al.* Epidemiologic study of *Blastocystis* infection in an urban community in the Philippines. *Journal of Environmental and Public Health.* 2015:7.
29. Roberts T, Stark D, Harkness J, Ellis J. Subtype distribution of *Blastocystis* isolates identified in a Sydney population and pathogenic potential of *Blastocystis.* *Eur J Clin Microbiol Infect Dis.* 2013;32(3):335-343.

30. Stensvold R, Brillowska-Dabrowska A, Nielsen HV, Arendrup MC. Detection of *Blastocystis hominis* in unpreserved stool specimens by using polymerase chain reaction. *J Parasitology*. 2006;92(5):1081-1087.
31. Nigro Luciano, Licia Larocca, Laura Massarelli. A placebo-controlled treatment trial of *Blastocystis hominis* infection with metronidazole. *Journal of Travel Medicine*. 2003;10:128-130.
32. Moghaddam DD, Ghadirian E, Azami M. *Blastocystis hominis* and the evaluation of efficacy of metronidazole and trimethoprim/sulfamethoxazole. *Parasitol Res*. 2005;96:273-275.
33. Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y. Clinical efficacy of *Saccharomyces boulardii* or metronidazole in symptomatic children with *Blastocystis hominis* infection. *Parasitol Res*. 2011;108:541-545.
34. Tan KS.W, Mirza H, Teo JD.W, Wu B, MacAry PA. Current views on the clinical relevance of *Blastocystis* spp. *curr Infect Dis Rep*. 2010;12:28-35.
35. Rajic B, Arapovic J, Ragu K, Boškovi M, Babi S M, Masla S. Eradication of *Blastocystis hominis* prevents the development of symptomatic Hashimoto's thyroiditis: a case report. *The Journal of Infection in Developing Countries*. 2015 ;9(7) :788-791.
36. Qadri H S M, Al-Okaili G A, Al-Dayel F. Clinical significance of *Blastocystis hominis*. *J Clin Microbiol*. 1989;27:11.
37. Alamlah L, Abufaied M, Al-Allaf A W. An unusual cause of reactive arthritis with urticarial : a case report. *Qatar Medical Journal*. 2020:25.
38. Vogelberg C, Stensvold C R, Monecke S, Ditzen A, Stopsack K, Heinrich-Gräfe U, Pohlmann C. *Blastocystis* sp. subtype 2 detection during recurrence of gastrointestinal and urticarial symptoms. *Parasitology international*. 2010;59: 469-471.
39. Tai W, Hu P, Wu J, Lin X. Six ulcerative colitis patients with refractory symptoms co-infective with *Blastocystis hominis* in china. *Parasitol Res*. 2011;108(5):1207-10.
40. Vezir S, Kaya F, Vezir E, Karaosmanoglu N, Adiloglu A K. Evaluation of intestinal parasites in patients with chronic spontaneous urticaria in a territory hospital in turkey. *The Journal of Infection in Developing Countries*. 2019;13(10):927-932.

41. Basyoni M M A, Fouad S A, Amer M F, Amer A F, Ismail D I. Atorvastatin : in-vivo synergy with metronidazol as anti-*blastocystis* therapy. *Korean J Parasitol*. 2018;2:105-112.
42. Verma R, Delfanian K. *Blastocystis hominis* associated acute urticaria. *The American Journal of the Medical Sciences*. 2013;346(1):80-81.
43. Nagel R, Cuttell L, Stensvold C R, Mills P C, Bielefeldt-ohmann H, Traub J. *Blastocystis* subtypes in symptomatic and asymptomatic family members and pets and response to therapy. *Internal Medicine Journal*. 2012;42:1445-5994.
44. Shah M, Tan C B, Rajan D, Ahmed S, Subramani K, Rizvon K, Mustacchia P. *Blastocystis hominis* and endolimax nana Co-Infection resulting in chronic diarrhea in an immunocompetent male. *Gastroenterol*. 2012;6:358-364.
45. Idris N S, Dwipoerwantoro P G, Kurniawan A, Said M. Intestinal parasitic infection of immunocompromised children with diarrhoea: clinical profile and therapeutic response. *J Infect Dev Ctries*. 2010;4(5):309-317.
46. Lee M G, Rawlins S C, Didier M, DeCeulaer K. Infective arthritis due to *Blastocystis hominis*. *Annals of the Rheumatic Diseases*. 1990;49:192-193.
47. Ocana-losada C, Cuenca-gomez J A, cabezas-fernandez M T, Vázquez-Villegas J, Soriano-Pérez M.J, Cabeza-Barrera I, Salas-Coronas J. Clinical and epidemiological characteristics of intestinal parasite infection by *Blastocystis hominis*. *Rev Clin Esp*. 2018;6.
48. Salvador F, Sulleiro E, Sánchez-Montalvá A, Alonso C, Santos J, Fuentes I, Molina I. Epidemiological and clinical profile of adult patients with *Blastocystis* sp. infection in Barcelona, Spain. *Parasitol & Vectors*. 2016;9:548.
49. Rajamanikam A, Kumar S, Samudi C, Kudva M. Exacerbated symptoms in *Blastocystis* sp. infected patients treated with metronidazol: two case studies. *Parasitology Res*. 2018;117(8):2585-2590.
50. O'gorman M A, Orenstein S R, Proujansky R, Wadowsky R M, Putnam P E, Kocoshis S A. Prevalence and Characteristics of *Blatocystis hominis* Infection in Children. *Clinical Pediatrics*. 2015;412;692-5180.
51. Zierdt CH. *Blastocystis hominis*, a protozoan parasite and intestinal pathogen of human beings. *Clin Microbiol Newsltr*. 1983; 5:57-59.
52. Rajamanikam A, Hooi H S, Kudva M, Samudi C, Kumar S. Resistance towards metronidazole in *Blastocystis* sp.: A pathogenic consequence. *PLoS ONE*. 2019; 14(2).

53. Miné JC, Rosa JA. Frequency of Blastocystis hominis and other intestinal parasites in stool samples examined at the Parasitology Laboratory of the School of Pharmaceutical Sciences at the São Paulo State University, Araraquara. *Rev Soc Bras Med Trop.* 2008;41:565-9.
54. Elghareeb AS, Younis MS, El Fakahany AF, Nagaty IM, Nagib MM. Laboratory diagnosis of Blastocystis sp. in diarrheic patients. *Tropical Parasitology.* 2015; 5:1.
55. Edwards DI. Nitromidazole drugs action and resistance mechanisms. I. Mechanisms of action. *J Antimicrob Chemother.* 1993; 1:9-20.
56. Samuelson J. Why metronidazole is active against both bacteria and parasites. *Antimicrob Agents Chemother.* 1999; 43: 1533-1541.
57. Müller M. Mode of action of metronidazole on aerobic bacteria and protozoa. *Surgery.* 1983; 93: 165- 171.
58. Tocher JH, Edwards DI. The interaction of reduced metronidazole with DNA bases and nucleosides. *Int J Radiat Oncol Biol Phys.* 1992;22(4):661-3.
59. Seiler J S , Herold R W. The use of systemic antibiotics in the treatment of aggressive periodontal disease. *Journal of General Dentistry.* 2005;155-159.
60. Gunawan, Gan Sulistia. Farmakologi dan terapi edisi 6. Departemen Farmakologi dan Terapeutik FKUI. Jakarta. 2016.
61. Pritt B S, Clark C G. Amebiasis. *Mayo Clin Proc.* 2008; 83: 1154-1160.
62. Peri W J R. Terapi protozoa usus. *Tren Parasitol.* 2003; 19: 523-526.
63. Mahajan C, Chitkara L, Vinayak vk. Evaluasi komparatif in vitro dari strain tinidazole dan metronidazol dari Entamoeba histolytica. *Bakteriol J Pathol India.*1974; 17: 226-228
64. Gardner TB and Hill DR. Treatment of Giardiasis. *Clin Mikrobiol Rev.* 2001;14(1):114-128.
65. Sears SD, O'Hare J. In vitro susceptibility of *Trichomonas vaginalis* to 50 antimicrobial agents. *Antimicrob Agents Chemother.*1988; 32(1): 144-146.
66. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. *Drug.*1997; 54(5): 679-708.

67. Pusat Informasi Obat Nasional (Pionas), Badan Pengawas Obat dan Makanan (BPOM) Republik Indonesia 2014, *Informatorium Obat Nasional Indonesia (IONI)*, BPOM RI.
68. Puthia MK, Vaithilingam A, Lu J, Tan KSW. Degradation of human secretory immunoglobulin a by *Blastocystis*. *Parasitol Res.* 2005;97(5):386- 389.
69. Abdel-Hameed DM, Hassanin OM. Protease activity of *Blastocystis hominis* subtype3 in symptomatic and asymptomatic patients. *Parasitol Res.* 2011;109(2):321-327.
70. Sio SWS, Puthia MK, Lee ASY, Lu J, Tan KSW. Protease activity of *Blastocystis hominis*. *Parasitology research.* 2006; 99(2):126–30.
71. Poirier P, Wawrzyniak I, Vivarès CP, Delbac F, El Alaoui H. New insights into *Blastocystis sp.*: A potential link with irritable bowel syndrome. *PLoS Pathog.* 2012;8(3).
72. Mavroudis G, Strid H, Jonefjäll B, Simrén M. Visceral hypersensitivity is together with psychological distress and female gender associated with severity of IBS-like symptoms in quiescent ulcerative colitis. *Neurogastroenterol motil.* 2021;33(3).
73. Gastrointestinal Protozoa. eTG Complete [digital]. Melbourne: Therapeutic Guidelines Limited, 2019.
74. Ikatan Dokter Indonesia. Panduan Praktik Klinis bagi Dokter di Fasilitas Pelayanan Kesehatan Primer. 1nd ed. Jakarta: Ikatan Dokter Indonesia; 2017.
75. Rodriguezp RC, Luna AJ. The pathogenicity of *Entamoeba histolytica* is related to the capacity of evading innate immunity. *Par Immunol.* 2005;27:1-8.
76. Cantellano ME, Palomo AM. Pathogenesis of intestinal amebiasis: from molecules to disease. *Clin Microbiol Rev.* 2000;13:318-31.
77. Stanley Jr SL, Reed SL. Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VI. *Entamoeba histolytica*: parasite-host interactions. *Amer J physiol.* 2001;280:1049-54.
78. Haresh K, Suresh K, Anuar AK, Saminathan S. Isolate resistance of *Blastocystis hominis* to metronidazole. *Trop Med Int Health.* 1999; 4(4): 274-7.

79. Roberts T, Ellis J, Harkness J, Marriott D, Stark D. Treatment failure in patients with chronic Blastocystis infection. *J Med Microbiol.* 2014;63:252-257.
80. Haque R, Ali IK, Akther S, Petri WA Jr. Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of *Entamoeba histolytica* infection. *J Clin Microbiol.* 1998; 36: 449-52.

